Full-Time

Senior Director Chemical Development

Treeline Biosciences

Treeline Biosciences

51-200 employees

Biotech firm discovering cancer therapies.

Compensation Overview

$230k - $277.8k/yr

Belmont, MA, USA

In Person

On-site in Watertown, MA. Up to 20% travel to CDMOs domestically and internationally.

Category
Biology & Biotech (1)
Required Skills
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Treeline Biosciences

See people who can refer or advise you

Requirements
  • Ph.D. in Organic Chemistry, Chemical Engineering, or related discipline with a minimum of 12+ years of experience, or a Master’s with a minimum of 15+ years of experience in small molecule drug substance development
  • Track record of success in leading and managing small-molecule drug substance programs in a 100% outsourced environment
  • Strong vendor/supplier management skills and excellent communication and cross-functional collaboration skills
  • Competency in developing, implementing and delivering CMC project plans (milestones, timelines, resources, etc.) to successful endpoints
  • Expertise in authoring and reviewing technical documents including, but not limited to, development reports, master batch records, analytical testing methods, and specifications
  • Thorough knowledge of the drug development process and ICH requirements for NDA and MAA registration. Extensive experience in working with regulatory authorities. Track record of authoring and defending Module 3 CTD content through regulatory approval and commercialization
  • Ability to articulate complex issues and ideas with clarity to enable understanding and decision making
  • Pragmatic, solution-oriented thinker who possesses a “can do” and “whatever it takes” attitude, coupled with excellent organizational and communication skills
  • Strong interpersonal and decision-making skills with the ability to motivate and influence others, negotiate during situational conflict, and establish the best forward path in the face of competing points of view
  • Understanding of industry trends, practices, techniques and standards, and associated impact on program strategy and execution
  • Ability to travel (20%) to CDMO domestic and international sites
  • Fluency with standard computer software packages (MS Word, Excel, PowerPoint, and Project) and JMP (or similar statistical tools)
  • High level of personal integrity, commitment to excellence and to our patients
  • Experience in developing and commercializing drugs for oncology is preferred
Responsibilities
  • Lead and manage cross-functional teams engaged in external cGMP manufacturing of drug substance, DS intermediates, and starting materials
  • Provide technical and functional project leadership on drug substance process development, manufacturing, and CDMO partner management
  • Lead and manage process transfers and associated site implementation to support supply chain expansion activities and continuous improvement initiatives
  • Monitor, track and trend process performance. Develop and implement data analytics to support investigations and provide an historical baseline for future operational and process-related improvements
  • Support investigations, root cause identification and CAPA implementation associated with manufacturing deviations and associated quality events
  • Work closely with Analytical Development/QC, Quality Assurance, Regulatory CMC, Supply Chain and external manufacturing operations to ensure operational excellence with respect to timelines, budgets, and attainment of technical, regulatory and business goals/milestones
  • Lead the selection of drug substance CDMOs based upon core capabilities, capacity and track record of regulatory compliance; establish KPIs to monitor site technical, quality and business performance
  • Develop and maintain strong relationships with CDMO business partners and participate in Steering Committees as appropriate
  • Review/approve technical reports, controlled GMP documents and CMC content for Module 3 CTDs
  • Develop and manage scope, milestones, interdependencies, budgets and timelines associated with drug substance program deliverables. Ensure cross-functional alignment of drug substance program deliverables with overall program strategy
  • Continuously monitor external business and regulatory environments; identify risks and establish mitigation plans and/or best practices to proactively address Drug Substance and supply chain risk
  • Represent the Technical Operations organization in meetings with FDA, EMA and related regulatory authorities
Desired Qualifications
  • Experience in oncology drug development and commercialization is preferred

Treeline Biosciences develops proprietary therapies for cancer and other serious diseases by conducting in-depth R&D across biology, chemistry, protein sciences, and computational science. Its product work involves discovering and optimizing drug candidates, then licensing these therapies to larger pharmaceutical companies or selling them to healthcare providers, with support from CRO collaborations to speed development. The company differentiates itself through a balanced mix of in-house research and external partnerships, a robust IP strategy, and a team that blends experienced biotech veterans with new talent, all backed by funding from KKR to scale operations. Its goal is to build a sustainable, long-term pipeline of treatments that can reach patients while expanding capabilities and partnerships in the biotech ecosystem.

Company Size

51-200

Company Stage

Series A

Total Funding

$1.1B

Headquarters

Stamford, Connecticut

Founded

2021

Get referred to Treeline Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Phase 1 data from the first three programs is expected in 2027.
  • TLN-499 is slated to enter the clinic in 2026, adding another catalyst.
  • More than $900 million in combined cash supports runway into 2029.

What critics are saying

  • All therapies remain investigational, so Treeline has no approved product revenue.
  • TLN-372 faces intense competition in crowded KRAS oncology programs.
  • TLN-254 inherits development risk from Hengrui's prior Phase 2-only progress.

What makes Treeline Biosciences unique

  • Treeline combines internally discovered assets with in-licensed programs from Jiangsu Hengrui Pharmaceuticals.
  • Its pipeline spans small molecules, protein degraders, and targeted therapy antibody-drug conjugates.
  • The company is advancing oncology programs while expanding into neurology and immunology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

0%
Endpoints News
Sep 3rd, 2025
Josh Bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B

Josh bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B.

Business Wire
Sep 3rd, 2025
Treeline Biosciences Secures $200M, Starts Trials

Treeline Biosciences announced the start of Phase 1 trials for three programs: TLN-121 (BCL6 degrader) and TLN-254 (EZH2 inhibitor) for lymphoma, and TLN-372 (pan-KRAS inhibitor) for KRAS-mutated cancers. They also secured a $200 million Series A extension, totaling $1.1 billion in funding. CEO Josh Bilenker highlighted their aim to create a leading biopharma company with innovative cancer treatments.

VentureCapital.com
Sep 3rd, 2025
Treeline Biosciences Commences Phase 1 Trials and Secures $200 Million Series A Extension Funding

Treeline Biosciences commences Phase 1 trials and secures $200 million Series A extension funding.

VC News Daily
Jan 5th, 2025
Treeline Biosciences Raises $421M Funding

Treeline Biosciences, a drug discovery startup based in Watertown, MA, has secured $421 million in October's largest fundraising round.

The Business Journals
Dec 30th, 2024
Treeline Biosciences raises $421.8M in 2024

Treeline Biosciences, based in Watertown, raised the largest venture capital round by a Massachusetts biotech in 2024, securing $422 million. Co-founded by Joshua Bilenker and Jeffrey Engelman, the company focuses on challenging molecular targets in oncology.